Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GSTM1 2944 GLUTATHIONE CHEMBL1543 DrugBank 17311259, 17381051, 17427177, 17624589, 17372252
GSTM1 2944 NITROGLYCERIN CHEMBL730 NCI 2110160
GSTM1 2944 SULFORAPHANE CHEMBL48802 NCI 16332662
GSTM1 2944 FLUOROTRYPTOPHANE CHEMBL559973 DrugBank 17139284, 17016423, 10592235
GSTM1 2944 IRINOTECAN CHEMBL481 NCI 16865249
GSTM1 2944 LUTEIN CHEMBL173929 NCI 15355982
GSTM1 2944 CHLORAMBUCIL CHEMBL515 NCI 15044619
GSTM1 2944 METHOTREXATE CHEMBL34259 NCI 17180579
GSTM1 2944 PREDNISONE CHEMBL635 NCI 11186134
GSTM1 2944 TROGLITAZONE CHEMBL408 NCI 12732844
GSTM1 2944 CURCUMIN CHEMBL116438 NCI 15044619
GSTM1 2944 DOCETAXEL CHEMBL92 NCI 16765145
GSTM1 2944 DICUMAROL CHEMBL1466 NCI 15044619

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GSTM1 GSTM1 non-null, GSTM1 null null azathioprine efficacy yes GSTM1 null is associated with decreased clinical benefit to azathioprine in children with Colitis, Ulcerative or Crohn Disease as compared to GSTM1 non-null. 30987408 1451237374
GSTM1 GSTM1 non-null, GSTM1 null null/null fluorouracil efficacy no Patients were taking either IFL (irinotecan + fluorouracil + leucovorin; n=114), FOLFOX (fluorouracil + oxaliplatin + leucovorin; n=299) or IROX (irinotecan + oxaliplatin; n=107). No significant association was seen between this variant and confirmed response rate, overall survival or time to progression in any of the treatment groups OR all treatment groups considered together. Significance level was set at 0.01. GSTM1 null/null is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to GSTM1 non-null/non-null + non-null/null. 20530282 1448522322
GSTM1 GSTM1 non-null, GSTM1 null null bevacizumab efficacy no No significant association with response, progression-free survival or overall survival was found for this variant. GSTM1 null is not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to GSTM1 non-null. 27995989 1448568334
GSTM1 GSTM1 non-null, GSTM1 null non-null paclitaxel efficacy yes Women with histologically confirmed ovarian cancer treated between 1996 and 2004. Treatment consisted of paclitaxel and cisplatin or carboplatin. This combination chemotherapy was the standard treatment for these patients. GSTM1 non-null is associated with decreased response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTM1 null. 26803611 1447711105
GSTM1 GSTM1 non-null, GSTM1 null null anthracyclines and related substances efficacy yes GSTM1 null is associated with decreased response to anthracyclines and related substances, capecitabine, cyclophosphamide, fluorouracil and taxanes in women with Breast Neoplasms as compared to GSTM1 non-null. 27785604 1448635326
GSTM1 GSTM1 non-null, GSTM1 null null gemcitabine metabolism/PK no GSTM1 null is not associated with clearance of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to GSTM1 non-null. 21590444 1446900787
GSTM1 GSTM1 non-null, GSTM1 null non-null/non-null bleomycin efficacy yes Patients with an extensive or ultrahigh activity GSTM1 genotype had a higher probability of achieving complete remission, as compared to those with a poor or intermediate activity GSTM1 genotype. Poor GSTM1 activity = null/null, intermediate = null/non-null, extensive = non-null/non-null and ultrahigh = more than two active genes resulting from a gene duplication event. No significant association was seen for freedom from treatment failure or progression-free survival in multivariate analysis. No significant association was seen for overall survival. GSTM1 non-null/non-null is associated with increased response to bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTM1 non-null/null + null/null. 23323945 1184166178
GSTM1 GSTM1 non-null, GSTM1 null null/null imatinib efficacy no However, CML patients who do not carry both the GSTT1 and GSTM1 genes were more likely to fail imatinib treatment (P<0.001). GSTM1 null/null is not associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to GSTM1 non-null/non-null + non-null/null. 25188725 1444672939
GSTM1 GSTM1 non-null, GSTM1 null null azathioprine metabolism/PK yes and the ratio of TGN/dose was lower in null individuals. GSTM1 null is associated with increased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to GSTM1 non-null. 23787247 1448262059
GSTM1 GSTM1 non-null, GSTM1 null null oxaliplatin efficacy no GSTM1 null is not associated with response to oxaliplatin in people with Colorectal Neoplasms as compared to GSTM1 non-null. 27636246 1448263407
GSTM1 GSTM1 non-null, GSTM1 null null azathioprine efficacy no as measured by relative genotype frequencies in patients with active disease status at 6 months of treatment. Authors state "this result was not fully significant likely because of the reduced number of patients in this subgroup." GSTM1 null is associated with decreased response to azathioprine in people with Inflammatory Bowel Diseases as compared to GSTM1 non-null. 23787247 1448262588